Shanta Gold's CEO explains the Q2 production shortfall and emphasises the cashflow strength of SGH. Watch the full video here.
Sorry but I cannot let that statement go unanswered. Firstly you just completely ignored the amazing Trial 1 results from Foralumab. Secondly the fact that Foralumab is not directly targeting Covid is its strength not its weakness, it will work regardless of mutations/variants! Thirdly, I for one have spent the last few weeks reading everything I can about how the immune system works and have come to the conclusion that both of TILS mAbs have equal ability to combat Covid, Foralumab more so because it appears to work much earlier in the anti-inflammation process.
Why don’t you do some real research!? You might learn something. I for one think we need the recognised TILS scientific experts on immunity for combating the Covid problem. If you think you can scare LTHs into selling their shares then you can just go jump in a lake!
>> I think you will find most of the 'derampers' you refer to have been invested in Tiziana a lot longer than you have !
Actually, and for the record, TILS is one of the first new shares I invested in after watching, by video link, my father die of Covid early in the first wave. A highly traumatic experience I wouldn’t wish on anyone. So, you could say I have skin in the game, i.e. I am a ‘Covid chaser’ for a reason, so more than just an investor, rightly or wrongly. (Yes I am also invested in SNG.)
Wake up people, we have a third wave on our shores! We have to hope that our jabs still work against whatever mutation comes next!
P.S. There have been several blatantly incorrect statements on this board over the last few weeks, which I will not go into. I remain positive. I will give TILS, and other Life Science companies time to develop the treatments we absolutely need, ...and some of us have to counteract the overblown negativity at times. I fully understand people’s frustrations, but too much bashing of a share you are invested in will not help.
Re: An Abu Dhabi investment fund has agreed to pay £800m into UK life sciences...
So that’s £800m up for grabs, in addition to the ‘UK's £200m Life Sciences Investment Programme’ which will be split how many ways I wonder!?
UK Life Sciences are some of the BEST in the World, we all need to support them NOT stamp on the green shoots or force them to uproot and grow elsewhere. This is such great news, yet one more reason to invest in TILS.
P.S. the recent deafening de-ramping is a sign of good news soon, in my opinion.
@iceman888 and @Bluebelly
I too have nothing but a positive outlook for my TILS holding and would like to tell all these de-rampers that their tricks are annoying, but their agendas are completely transparent. Personally this kind of silence gives me more anticipation that there will be an explosion upward into that second shoulder soon. LTHs should focus on the longer term prize and not get fooled by the many psychological tricks deployed on this board. I find some of this highly distasteful at best.
Nothing has changed in my view to darken this gem, and good things come to all those who wait... of course we must all do our own research and come to our own conclusions, but the great technology and patented pipeline offerings have NOT changed, in fact they just get more and more enticing day by day from other news (e.g. the finding of long term inflammation on long Covid suffers, the double mutation variants, all the other companies moving to nasal technology, etc.). If I didn’t have my other favoured rockets I would continue to fill my boots with shares at these bargain prices. (Or perhaps some better advice, wait until the 3rd wave news has finished lowering ALL of the launch areas/boats, as that’s what’s happening right now.)
If TILS have been talking to the UK government then we all know how slow the government are and how much they keep things under wraps.
I am hopeful here. Some thoughts, possibly over simplified: there are currently at least 3 types of approaches to treatment for Covid:
2. Anti inflammatory.
3. Immunity booster.
I would hope that new trials would want to cover all types, esp. with the concerns that antivirals can be ‘escaped’ by new variants. The results for Ivermectin/niclosamide look good, but I believe that is mainly working as an antiviral albeit it has some anti inflammatory effects as well (so more 1 + 2). Correct me anyone if I am wrong but I think SNG is more 2 + 3, whereas TILS Foralumab is more 3 + 2. All will have their strengths and weaknesses.
It seems that everyone is turning to the nasal/inhalation route now though! The combination of both TILS mAbs, Foralumab and TZL-501? would be: 1 + 2 + 3 !
A paragraph from that last article is really bad, either a/the more vaccine resistant variant is worse than feared or some useless Russian/Chinese vaccines are being used in Hungary.
‘ With about 9.6 million people, the Associated Press recently reported that Hungary had emerged as the EU’s vaccination star amid surging cases as the shortages of vaccine product impacting much of Europe was mitigated by a strategy that sought vaccine doses from Russia and China as well as from inside the EU.
But as recently reported, this strategy is now put to the test due to skyrocketing cases as well as deaths (150 on average per day) caused by the UK variant, experts believe.’
I have a friend in Hungary and very sadly both his parents are now seriously ill with Covid. I don’t yet know if they were vaccinated recently.
Another study in Hungary using a branded version of niclosamide:
Merck’s Stromectol (Ivermectin)
About the Union Therapeutics drug:
Uses for niclosamide
Niclosamide belongs to the family of medicines called anthelmintics. Anthelmintics are medicines used in the treatment of worm infections.
Niclosamide is used to treat broad or fish tapeworm, dwarf tapeworm, and beef tapeworm infections.
What!? There’s a joke in there somewhere...
From Union Therapeutics:
Niclosamide is a potent inhibitor of SARS-CoV-2 with potency >40x higher than remdesivir as demonstrated by Institut Pasteur Korea
The sinonasal cavity is considered a major site of early infection by SARS-CoV-2 and a major factor in transmission.
Intranasal administration of niclosamide has been demonstrated to prevent fatal outcomes in a murine challenge model
UNI91103 is a nasal spray pump delivering a concentrated niclosamide salt solution to the nasal cavity
UNI91103 has been tested in 44 healthy volunteers with positive results
UNI91103 is being prepared for clinical trials in subjects at high risk of contracting COVID-19
‘Candidates will be selected by government advisors’! Of course, but none revealed yet.
One candidate chosen already from Denmark:
II’s will average down as the price drops, to buy back in later, that seems to be standard practice. No-one can time the good news perfectly. That doesn’t mean anything for LTH’s. Lots of research and a bit of faith is my approach. Doesn’t usually fail me.
I found some more Covid variant news, the salient points as follows:
‘A February laboratory study suggested the South African variant may reduce antibody protection from the Pfizer and BioNTech vaccine by two-thirds, while reducing the impact on neutralization of Moderna’s vaccine six-fold. ‘
and about the efficacy of AZN vs South African variant:
‘ Virus neutralisation activity by vaccineinduced antibodies was 9-fold lower against the B.1.1.7 variant than against a canonical non B.1.1.7 lineage.’
Sorry if that makes for grim reading.
I grabbed a few more shares before the inevitable rise and the inverted TILS man shoulder/arm will be created fully. My last top up now otherwise I bust my % limit for a single share in my diversified portfolio. I used to have well over 40 stocks across 4 different pots, SIPPs, ISA. But down to half that now as I have concentrated on the hottest smoking rockets. Always tough decisions, missed a couple of smaller rocket launches in the refinements. Oh well, can’t win them all...
Come on TILS, I have faith...
P.S. Holding long term here so you can forget the psychological tricks de-rampers...